Advertisement

Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis

  • Alessandro Rizzo
    Correspondence
    Address for correspondence: Alessandro Rizzo, Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II," Viale Orazio Flacco 65, 70124 Bari, Italy
    Affiliations
    Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II," Bari, Italy
    Search for articles by this author
  • Veronica Mollica
    Affiliations
    Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
    Search for articles by this author
  • Matteo Santoni
    Affiliations
    Oncology Unit, Macerata Hospital, Macerata, Italy
    Search for articles by this author
  • Francesco Massari
    Affiliations
    Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    Search for articles by this author

      Abstract

      Background

      Upper tract urothelial carcinomas (UTUCs) arise in the renal pelvis or the ureter, accounting for approximately 5% of all urothelial carcinomas. Recent years have witnessed the publication of several studies aimed at assessing the molecular, biologic, and clinical features of UTUC, reporting that FGFR3 mutations are the most observed genetic aberrations; however, several knowledge gaps persist in the understanding of the genomic landscape of this genitourinary malignancy with few treatment options.

      Patients and Methods

      In the current study, we aimed to comprehensively analyze clinicopathological features of FGFR3-mutated UTUCs patients in public datasets to increase the current knowledge of the molecular and biologic profile of UTUC. Data regarding clinical outcomes, mutational profiles, and copy number alterations in patients affected by UTUC were downloaded from the cBioPortal for Cancer Genomics Database. UTUC data were available from 4 studies, for a total number of 358 patients; among these, 150 UTUC patients presented FGFR3 mutations.

      Results

      The current database analysis of the mutational profile of 150 FGFR3-mutated UTUCs suggested that FGFR3 mutations may represent a prognostic factor in this disease, with a statistically longer overall survival compared to wild-type patients treated with radical surgery. In addition, FGFR3 mutations were more frequent in low-grade UTUCs with early-stage disease (pT1, pT2, and pT3).

      Conclusion

      Genomic characterization of UTUC is destined to become increasingly important, and more efforts aimed at implementing UTUC genomics analysis are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rouprêt M
        • Babjuk M
        • Compérat E
        • et al.
        European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update.
        Eur Urol. 2018; 73: 111-122https://doi.org/10.1016/j.eururo.2017.07.036
        • Rouprêt M
        • Babjuk M
        • Burger M
        • et al.
        European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update.
        Eur Urol. 2021; 79: 62-79https://doi.org/10.1016/j.eururo.2020.05.042
        • Freifeld Y
        • Krabbe LM
        • Clinton TN
        • Woldu SL
        • Margulis V.
        Therapeutic strategies for upper tract urothelial carcinoma.
        Expert Rev Anticancer Ther. 2018; 18: 765-774https://doi.org/10.1080/14737140.2018.1481395
        • Soria F
        • Shariat SF
        • Lerner SP
        • et al.
        Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).
        World J Urol. 2017; 35: 379-387https://doi.org/10.1007/s00345-016-1928-x
        • Inamoto T
        • Matsuyama H
        • Ibuki N
        • et al.
        Biological behavior and long-term outcomes of carcinoma in situ in upper urinary tract managed by radical nephroureterectomy.
        J Urol. 2018; 199: 933-939https://doi.org/10.1016/j.juro.2017.10.019
        • Wu J
        • Chen S
        • Wu X
        • et al.
        Trends of incidence and prognosis of upper tract urothelial carcinoma.
        Bosn J Basic Med Sci. 2021; 21: 607-619https://doi.org/10.17305/bjbms.2020.5345
        • Deuker M
        • Stolzenbach LF
        • Collà Ruvolo C
        • et al.
        Upper urinary tract tumors: variant histology versus urothelial carcinoma.
        Clin Genitourin Cancer. 2021; 19: 117-124https://doi.org/10.1016/j.clgc.2020.11.004
        • Nazzani S
        • Mazzone E
        • Preisser F
        • et al.
        Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma.
        Eur J Surg Oncol. 2019; 45: 1238-1245https://doi.org/10.1016/j.ejso.2018.12.004
        • Birtle A
        • Johnson M
        • Chester J
        • et al.
        Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
        Lancet. 2020; 395: 1268-1277https://doi.org/10.1016/S0140-6736(20)30415-3
        • Kammerer-Jacquet SF
        • Mathieu R
        • Peyronnet B
        • Rioux-Leclercq N
        • Bensalah K.
        Genomics in upper tract urothelial carcinoma.
        Curr Opin Urol. 2017; 27: 35-40https://doi.org/10.1097/MOU.0000000000000341
        • Necchi A
        • Madison R
        • Pal SK
        • et al.
        Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma.
        Eur Urol Focus. 2021; 7: 1339-1346https://doi.org/10.1016/j.euf.2020.08.001
        • Yang K
        • Yu W
        • Liu H
        • et al.
        Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder.
        Oncologist. 2021; 26: e1395-e1405https://doi.org/10.1002/onco.13839
        • Audenet F
        • Isharwal S
        • Cha EK
        • et al.
        Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma.
        Clin Cancer Res. 2019; 25: 967-976https://doi.org/10.1158/1078-0432.CCR-18-2039
        • Kim K
        • Hu W
        • Audenet F
        • et al.
        Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.
        Nat Commun. 2020; 11: 1975https://doi.org/10.1038/s41467-020-15885-7
        • Su X
        • Lu X
        • Bazai SK
        • et al.
        Comprehensive integrative profiling of upper tract urothelial carcinomas.
        Genome Biol. 2021; 22: 7https://doi.org/10.1186/s13059-020-02230-w
        • Robinson BD
        • Vlachostergios PJ
        • Bhinder B
        • et al.
        Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
        Nat Commun. 2019; 10: 2977https://doi.org/10.1038/s41467-019-10873-y
        • Sfakianos JP
        • Cha EK
        • Iyer G
        • et al.
        Genomic characterization of upper tract urothelial carcinoma.
        Eur Urol. 2015; 68: 970-977https://doi.org/10.1016/j.eururo.2015.07.039
        • Bagrodia A
        • Cha EK
        • Sfakianos JP
        • et al.
        Genomic biomarkers for the prediction of stage and prognosis of upper tract urothelial carcinoma.
        J Urol. 2016; 195: 1684-1689https://doi.org/10.1016/j.juro.2016.01.006
        • Moss TJ
        • Qi Y
        • Xi L
        • et al.
        Comprehensive genomic characterization of upper tract urothelial carcinoma.
        Eur Urol. 2017; 72: 641-649https://doi.org/10.1016/j.eururo.2017.05.048
        • Ricci AD
        • Rizzo A
        • Mollica V
        • et al.
        Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data.
        Anticancer Drugs. 2022; 33: e61-e68https://doi.org/10.1097/CAD.0000000000001200
        • Font A
        • Luque R
        • Villa JC
        • et al.
        The challenge of managing bladder cancer and upper tract urothelial carcinoma: a review with treatment recommendations from the spanish oncology genitourinary group (SOGUG).
        Target Oncol. 2019; 14: 15-32https://doi.org/10.1007/s11523-019-00619-7